These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 33830168)

  • 1. Assessment of a Contralateral Esophagus-Sparing Technique in Locally Advanced Lung Cancer Treated With High-Dose Chemoradiation: A Phase 1 Nonrandomized Clinical Trial.
    Kamran SC; Yeap BY; Ulysse CA; Cronin C; Bowes CL; Durgin B; Gainor JF; Khandekar MJ; Tansky JY; Keane FK; Olsen CC; Willers H
    JAMA Oncol; 2021 Jun; 7(6):910-914. PubMed ID: 33830168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Contralateral Esophagus-Sparing Technique to Limit Severe Esophagitis Associated With Concurrent High-Dose Radiation and Chemotherapy in Patients With Thoracic Malignancies.
    Al-Halabi H; Paetzold P; Sharp GC; Olsen C; Willers H
    Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):803-10. PubMed ID: 26104934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palliative Radiation for Advanced Central Lung Tumors With Intentional Avoidance of the Esophagus (PROACTIVE): A Phase 3 Randomized Clinical Trial.
    Louie AV; Granton PV; Fairchild A; Bezjak A; Gopaul D; Mulroy L; Brade A; Warner A; Debenham B; Bowes D; Kuk J; Sun A; Hoover D; Rodrigues GB; Palma DA
    JAMA Oncol; 2022 Apr; 8(4):1-7. PubMed ID: 35201290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.
    Bar-Ad V; Leiby B; Witek M; Xiao Y; Cui Y; Dai Y; Cao J; Axelrod R; Campling B; Both S; Werner-Wasik M
    Am J Clin Oncol; 2014 Oct; 37(5):433-7. PubMed ID: 23388558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial.
    Tachihara M; Tsujino K; Ishihara T; Hayashi H; Sato Y; Kurata T; Sugawara S; Shiraishi Y; Teraoka S; Azuma K; Daga H; Yamaguchi M; Kodaira T; Satouchi M; Shimokawa M; Yamamoto N; Nakagawa K;
    JAMA Oncol; 2023 Nov; 9(11):1505-1513. PubMed ID: 37676681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Wu TC; Luterstein E; Neilsen BK; Goldman JW; Garon EB; Lee JM; Felix C; Cao M; Tenn SE; Low DA; Kupelian PA; Steinberg ML; Lee P
    JAMA Oncol; 2024 Mar; 10(3):352-359. PubMed ID: 38206614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
    Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
    Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
    Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.
    Takeda K; Nemoto K; Saito H; Ogawa Y; Takai Y; Yamada S
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):626-9. PubMed ID: 15936536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.
    Ma L; Qiu B; Li Q; Chen L; Wang B; Hu Y; Liu M; Zhang L; Huang Y; Deng X; Xia Y; Lin M; Liu H
    Radiat Oncol; 2018 Jul; 13(1):130. PubMed ID: 30016978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.
    Singh AK; Lockett MA; Bradley JD
    Int J Radiat Oncol Biol Phys; 2003 Feb; 55(2):337-41. PubMed ID: 12527046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced frequency and severity of radiation esophagitis without marginal failure risk by contralateral esophagus sparing IMRT in stage III non-small cell lung cancer patients undergoing definitive concurrent chemoradiotherapy.
    Lim HS; Yang K; Noh JM; Pyo H; Kim JM; Kwon D; Ju SG; Ahn YC
    Radiother Oncol; 2024 Oct; 199():110436. PubMed ID: 39029592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Full Dose SBRT in Combination With Mediastinal Chemoradiation for Locally Advanced, Non-Small Cell Lung Cancer: A Practical Guide for Planning, Dosimetric Results From a Phase 2 Study, and a Treatment Planning Guide for the Phase 3 NRG Oncology LU-008 Trial.
    Heinzerling JH; Pen OV; Robinson M; Foster R; Kelly B; Mileham KF; Moeller B; Prabhu RS; Corso C; Ward MW; Sullivan CM; Burri S; Simone CB
    Pract Radiat Oncol; 2023; 13(6):531-539. PubMed ID: 37406774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.
    Chen D; Menon H; Verma V; Seyedin SN; Ajani JA; Hofstetter WL; Nguyen QN; Chang JY; Gomez DR; Amini A; Swisher SG; Blum MA; Younes AI; Barsoumian HB; Erasmus JJ; Lee JH; Bhutani MS; Hess KR; Minsky BD; Welsh JW
    JAMA Oncol; 2019 Nov; 5(11):1597-1604. PubMed ID: 31529018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
    Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
    Ross HJ; Kozono D; Wang XF; Urbanic JJ; Williams TM; Nelson GD; Carbone DP; Chung D; Robb R; Byun WY; Talabere T; DuFrane C; Bara I; Schulze K; Brockman M; Gao J; Vokes EE; Stinchcombe TE
    JAMA Oncol; 2024 Sep; 10(9):1212-1219. PubMed ID: 39052256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma.
    Bradley J; Deasy JO; Bentzen S; El-Naqa I
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1106-13. PubMed ID: 15001251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy 
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).
    Zehentmayr F; Söhn M; Exeli AK; Wurstbauer K; Tröller A; Deutschmann H; Fastner G; Fussl C; Steininger P; Kranzinger M; Belka C; Studnicka M; Sedlmayer F
    Radiat Oncol; 2015 May; 10():121. PubMed ID: 26018527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.